The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Development and validation of an immune gene-set based Prognostic signature in ovarian cancer
Open accessAbstract
BACKGROUND: Ovarian cancer (OV) is the most lethal gynecological cancer in women. We aim to develop a generalized, individualized immune prognostic signature that can stratify and predict overall survival for ovarian cancer. METHODS: The gene expression profiles of ovarian cancer tumor tissue samples were collected from 17 public cohorts, including 2777 cases totally. Single sample gene set enrichment (ssGSEA) analysis was used for the immune genes from ImmPort database to develop an immune-based prognostic score for OV (IPSOV). The signature was trained and validated in six independent datasets (n = 519, 409, 606, 634, 415, 194). FINDINGS: ]). Further, we compared IPSOV with nine reported ovarian cancer prognostic signatures as well as the clinical characteristics including stage, grade and debulking status. The IPSOV achieved the highest mean C-index (0.625) compared with the other signatures (0.516 to 0.602) and clinical characteristics (0.555 to 0.583). Further, we integrated IPSOV with stage, grade and debulking, which showed improved prognostic accuracy than clinical characteristics only. INTERPRETATION: The proposed clinical-immune signature is a promising biomarker for estimating overall survival in ovarian cancer. Prospective studies are needed to further validate its analytical accuracy and test the clinical utility. FUND: This work was supported by National Key Research and Development Program of China, National Natural Science Foundation of China and Natural Science Foundation of the Jiangsu Higher Education Institutions of China.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Yu, G., Wang, L.-G., Han, Y., & He, Q.-Y. (2012) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2011.0118 · Cited by 36,259
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
The prognostic landscape of genes and infiltrating immune cells across human cancers
Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Xu, Y., Khuong, A., Hoang, C. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3909 · Cited by 3,118
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206
A cytokine-mediated link between innate immunity, inflammation, and cancer
Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940 · cited 1×
“Cytokines and cytokine receptors processes play important roles in inflammatory, angiogenesis and chemotaxis processes [26].”
BackgroundCrosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
Self-citationImmunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Cytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1252 · Cited by 1,573
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
Self-citationStromal gene expression defines poor-prognosis subtypes in colorectal cancer
Calon, A., Lonardo, E., Berenguer-Llergo, A., Espinet, E., Hernando-Momblona, X., Iglesias, M., Sevillano, M., Palomo-Ponce, S., Tauriello, D. V. F., Byrom, D., et al. (2015) · Nature Genetics · doi:10.1038/ng.3225 · Cited by 1,070
Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy
Santarpia, L., Lippman, S. M., & El-Naggar, A. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.645805 · Cited by 1,027
A 17-gene stemness score for rapid determination of risk in acute leukaemia
Ng, S. W. K., Mitchell, A., Kennedy, J. A., Chen, W. C., McLeod, J., Ibrahimova, N., Arruda, A., Popescu, A., Gupta, V., Schimmer, A. D., et al. (2016) · Nature · doi:10.1038/nature20598 · Cited by 912
ImmPort: disseminating data to the public for the future of immunology
Bhattacharya, S., Andorf, S., Gomes, L., Dunn, P., Schaefer, H., Pontius, J., Berger, P., Desborough, V., Smith, T., Campbell, J., et al. (2014) · Immunologic Research · doi:10.1007/s12026-014-8516-1 · Cited by 806
Cytokines in Cancer Immunotherapy
Lee, S., & Margolin, K. (2011) · Cancers · doi:10.3390/cancers3043856 · Cited by 693
Angell, H., & Galon, J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.03.004 · Cited by 574
Li, B., Cui, Y., Diehn, M., & Li, R. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1609 · Cited by 514
Kang, L., Chen, W., Petrick, N. A., & Gallas, B. D. (2015) · Statistics in Medicine · doi:10.1002/sim.6370 · Cited by 420
Friday, B. B., & Adjei, A. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4790 · Cited by 374
Hu, L., Hofmann, J., Lu, Y., Mills, G. B., & Jaffe, R. B. (2002) · PubMed · Cited by 361
Gene Expression-Based Prognostic Signatures in Lung Cancer: Ready for Clinical Use?
Subramanian, J., & Simon, R. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq025 · Cited by 351
Rattan, R., Graham, R. P., Maguire, J. L., Giri, S., & Shridhar, V. (2011) · Neoplasia · doi:10.1593/neo.11148 · Cited by 316
Strategies for aggregating gene expression data: The collapseRows R function
Miller, J. A., Cai, C., Langfelder, P., Geschwind, D. H., Kurian, S. M., Salomon, D. R., & Horvath, S. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-322 · Cited by 297
Cancer immunology—analysis of host and tumor factors for personalized medicine
Ogino, S., Galon, J., Fuchs, C. S., & Dranoff, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.122 · Cited by 284
Mok, S. C., Bonome, T., Vathipadiekal, V., Bell, A., Johnson, M. E., Wong, K.-K., Park, D.-C., Hao, K., Yip, D. K. P., Donninger, H., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.018 · Cited by 255
Masoumi Moghaddam, S., Amini, A., Morris, D. L., & Pourgholami, M. H. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9337-5 · Cited by 228
Yoshihara, K., Tsunoda, T., Shigemizu, D., Fujiwara, H., Hatae, M., Fujiwara, H., Masuzaki, H., Katabuchi, H., Kawakami, Y., Okamoto, A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2725 · Cited by 189
Siu, M. K. Y., Chan, H. Y., Kong, D. S. H., Wong, E. S. Y., Wong, O. G. W., Ngan, H. Y. S., Tam, K. F., Zhang, H., Li, Z., Chan, Q. K. Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907481107 · Cited by 177
Immunotherapy for Ovarian Cancer: What's Next?
Kandalaft, L. E., Powell, D. J., Singh, N., & Coukos, G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2369 · Cited by 164
Antibody Immunity to the p53 Oncogenic Protein Is a Prognostic Indicator in Ovarian Cancer
Goodell, V., Salazar, L. G., Urban, N. D., Drescher, C. W., Gray, H. J., Swensen, R. E., McIntosh, M. W., & Disis, M. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2813 · Cited by 149
Comparative Meta-analysis of Prognostic Gene Signatures for Late-Stage Ovarian Cancer
Waldron, L., Haibe‐Kains, B., Culhane, A. C., Riester, M., Ding, J., Wang, V., Ahmadifar, M., Tyekucheva, S., Bernau, C., Risch, T., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju049 · Cited by 137
Tang, M. K. S., Zhou, H., Yam, J. W. P., & Wong, A. S. T. (2010) · Neoplasia · doi:10.1593/neo.91438 · Cited by 115
Shen, S., Wang, G., Shi, Q., Zhang, R., Zhao, Y., Wei, Y., Chen, F., & Christiani, D. C. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0392-9 · Cited by 73
Self-citationShen, S., Bai, J., Wei, Y., Wang, G., Li, Q., Zhang, R., Duan, W., Yang, S., Du, M., Zhao, Y., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.6057 · Cited by 36
Self-citationRe: Gene Expression-Based Prognostic Signatures in Lung Cancer: Ready for Clinical Use?
Boutros, P. C., Pintilie, M., John, T., Starmans, M. H. W., Der, S. D., Shepherd, F. A., Tsao, M., & Jurišica, I. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq385 · Cited by 6
Response: Re: Gene Expression-Based Prognostic Signatures in Lung Cancer: Ready for Clinical Use?
Subramanian, J., & Simon, R. M. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq386 · Cited by 4
Cited by
Liu, C.-J., Hu, F.-F., Xie, G.-Y., Miao, Y.-R., Li, X.-W., Zeng, Y., & Guo, A.-Y. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbac558 · Cited by 588
Pan-cancer characterization of immune-related lncRNAs identifies potential oncogenic biomarkers
Li, Y., Jiang, T., Zhou, W., Li, J., Li, X., Wang, Q., Jin, X., Yin, J., Chen, L., Zhang, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14802-2 · Cited by 414
Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma
Long, J., Wang, A., Bai, Y., Lin, J., Yang, X., Wang, D., Yang, X., Jiang, Y., & Zhao, H. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.022 · Cited by 380
Metadata
- Authors
- Shen, S., Wang, G., Zhang, R., Zhao, Y., Yu, H., Wei, Y., & Chen, F.
- Venue
- EBioMedicine
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 40
- Pages
- 318-326
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W2907123184
- Cited by
- 257
- References
- 39
- FWCI
- 27.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.